PROF

• Matthew Sobczyk, previously Corporate Controller, was appointed Interim Chief Financial Officer effective August 14, 2026.
• Sobczyk will receive an annual base salary of CAD 300,414.58 and is eligible for a discretionary bonus target of 15% of base salary.
• Dewan will receive a cash severance of $375,000, 15 months of employer-paid benefits, extended option exercise period, and up to CAD 5,000 in legal fee reimbursement.
• Dewan will earn CAD 200 per hour for consulting and continue vesting of 20,000 restricted share units.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The new software adds real-time iMRI control and physician-requested user interface and hardware improvements, building on TULSA-AI modules to increase procedural efficiency.
• The company says the software provides a roadmap for surgeons to achieve up to six TULSA Procedures per system per day, up from the four procedures some physicians currently report.
• CEO Arun Menawat stated the upgrade enhances TULSA-PRO's supervised robotic autonomy, potentially supporting future incisionless telesurgery.
• The disclosure was furnished under Item 7.01 Regulation FD and is not deemed filed for SEC purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• On August 13, 2026, Profound Medical Corp. announced the launch of Let's Huddle, a patient advocacy initiative.
• Let's Huddle provides educational resources, real patient stories, peer-to-peer engagement, and support for families and care partners.
• The press release was furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.
• The information is furnished and not deemed filed under the Exchange Act.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Approximately $3.1 million of TULSA product shipments shifted to Q3 due to a temporary logistics issue; excluding this, Q2 revenue would have been about $5.6 million, up 153% year-over-year.
• Gross margin expanded to 78% in Q2 2026 from 73% in the prior-year period.
• Operating expenses declined 16% year-over-year to approximately $13.0 million.
• Net loss improved 39% to approximately $9.5 million ($0.26 per share) from $15.7 million ($0.52 per share) in Q2 2025.
• Company reiterates full-year 2026 revenue guidance of approximately $25.0 million, representing 56% growth, and expects gross margin of 70% or higher.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• At 1 month post-treatment, whole-gland TULSA ablation showed no median change in penile length, versus a median 0.65 cm reduction after robotic radical prostatectomy.
• The between-arm difference in penile length change was statistically significant (0.42 cm; p<0.001), as presented at the Society of Robotic Surgery Annual Meeting.
• CAPTAIN enrolled 211 patients at 23 sites (20 US, 2 Canada, 1 Europe) by August 2025, exceeding its target of 201.
• The disclosure was furnished under Item 7.01 Regulation FD and is not deemed filed for SEC purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Profound Medical Corp. announced it will release second quarter 2026 financial results after market close on Thursday, August 6, 2026.
• The press release was issued on July 16, 2026 and is furnished as Exhibit 99.1 to the Form 8-K.
• The information is furnished under Item 7.01 Regulation FD Disclosure and is not deemed filed for SEC purposes.
• The company is a commercial-stage medical device company focused on interventional MRI procedures.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Profound Medical Corp. issued a press release on July 15, 2026, announcing that its TULSA Procedure will be highlighted in multiple presentations at the Society of Robotic Surgery (SRS) Annual Meeting in Fort Lauderdale, FL, July 23-26, 2026.
• Profound was selected as one of eight companies to be spotlighted in the Society of Incisionless Surgery (SIS) plenary session at SRS2026, featuring a talk by Dr. Y. Mark Hong on July 26, 2026.
• Profound's management will participate in an SRS Investor Session on July 22, 2026, moderated by analysts Rick Wise (Stifel) and Larry Biegelsen (Wells Fargo).
• The information was furnished under Item 7.01 Regulation FD Disclosure and is not deemed filed for SEC purposes.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Shareholders approved the appointment of PricewaterhouseCoopers LLP as auditors with 25,193,910 votes for (99.497%) and 127,301 withheld.
• Shareholders approved the ordinary resolution for unallocated restricted share units and deferred share units under the long-term incentive plan, with 9,046,376 votes for (63.922%) and 5,105,787 against.
• The meeting was held at the company's Mississauga, Ontario headquarters and was broadcast via webcast.
• The results were reported under Item 5.07 as a submission of matters to a vote of security holders.

5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits